Latest & greatest articles for amiodarone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on amiodarone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on amiodarone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for amiodarone

21. Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure. Analysis From the Sudden Cardiac Death in Heart Failure Trial

Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure. Analysis From the Sudden Cardiac Death in Heart Failure Trial 19917887 2009 12 01 2010 01 05 2016 12 15 1524-4539 120 22 2009 Dec 01 Circulation Circulation Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. 2170-6 (...) randomized 2521 subjects to placebo, amiodarone, or shock-only, single-lead ICD therapy. Over a median follow-up of 45.5 months, a total of 666 deaths occurred, which were reviewed by an Events Committee and initially categorized as cardiac or noncardiac. Cardiac deaths were further adjudicated as resulting from sudden death presumed to be ventricular tachyarrhythmic, bradyarrhythmia, heart failure, or other cardiac causes. ICD therapy significantly reduced cardiac mortality compared with placebo

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

22. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation

Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation 19487941 2009 06 18 2009 07 07 2013 11 21 1530-0293 37 7 2009 Jul Critical care medicine Crit. Care Med. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation. 2174-9; quiz 2180 10.1097/CCM.0b013e3181a02f56 To compare (...) the clinical efficacy of intravenous diltiazem, digoxin, and amiodarone for acute ventricular rate (VR) control in patients with acute symptomatic atrial fibrillation (AF) necessitating hospitalization. Randomized control trial. Acute emergency medical admission unit in a regional teaching hospital in Hong Kong. One hundred fifty adult patients with acute AF and rapid VR (>120 bpm). Patients were randomly assigned in 1:1:1 ratio to receive intravenous diltiazem, digoxin, or amiodarone for VR control

EvidenceUpdates2009

23. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation

Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF CRD summary This review compared the efficacy and safety (...) of dronedarone versus amiodarone for the prevention of recurrent atrial fibrillation. It concluded that dronedarone was less effective than amiodarone, but had fewer adverse events. Limitations in the conduct and reporting of this review mean that the estimates on which these conclusions were based may not be reliable. Authors' objectives To compare the efficacy and safety of dronedarone versus amiodarone for the prevention of recurrent atrial fibrillation. Searching MEDLINE was searched from inception

DARE.2009

24. Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis

Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis Doyle JF, Ho KM CRD summary This meta-analysis assessed the efficacy and safety of amiodarone compared with placebo or rate-control drugs for treating persistent atrial fibrillation (...) , in terms of mortality, rhythm control, withdrawal from treatment, and hospitalisation. The authors concluded that amiodarone was safe and effective, but some patients might be unable to tolerate it. These conclusions appear to be broadly reliable. Authors' objectives To assess the effectiveness and safety of amiodarone, compared with a placebo or rate-control drug, in achieving sinus rhythm in patients with atrial fibrillation persisting for more than 30 days. Searching MEDLINE (1966 to 2008), EMBASE

DARE.2009

25. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials

Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials Piccini JP, Berger JS, O'Connor CM CRD summary This review concluded that for people at risk of sudden cardiac death (post-myocardial infarction or with heart failure) amiodarone reduced (...) cardiac and cardiovascular death, but not overall mortality. Although there were adverse effects and the discontinuation rate was relatively high, amiodarone should be considered for people not eligible for cardioverter defibrillators. Overall the review was well-conducted and conclusions appear reliable. Authors' objectives To assess the efficacy and safety of amiodarone in preventing sudden death. Searching MEDLINE (1966 to 2007) and Cochrane Central Register of Controlled Trials (CENTRAL) were

DARE.2009

26. Amiodarone as a First-Line Therapy for the Conversion of Atrial Fibrillation or Long-term Maintenance of Sinus Rhythm Once Cardioversion Has Been Achieved

Amiodarone as a First-Line Therapy for the Conversion of Atrial Fibrillation or Long-term Maintenance of Sinus Rhythm Once Cardioversion Has Been Achieved "Amiodarone as a First-Line Therapy for the Conversion of Atrial Fibril" by Nicole Marie Dwyer < > > > > > Title Author Date of Award 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor James Ferguson, PA-C Second Advisor Rob Rosenow PharmD, OD Third Advisor Annjanette Sommers MS (...) , PA-C Rights This work is licensed under a . Abstract Background: Optimal, long-term drug strategies for cardioversion of atrial fibrillation (AF) and maintenance of sinus rhythm (SR) have been controversial. Amiodarone is an old drug that is an effective class III antiarrhythmic for both converting and maintaining sinus rhythm in patients with atrial fibrillation, however, there have been few recent, blinded, randomized controlled studies comparing amiodarone to other pharmacological agents

Pacific University EBM Capstone Project2009

27. Amiodarone cost effectiveness in preventing atrial fibrillation after coronary artery bypass graft surgery

Amiodarone cost effectiveness in preventing atrial fibrillation after coronary artery bypass graft surgery Amiodarone cost effectiveness in preventing atrial fibrillation after coronary artery bypass graft surgery Amiodarone cost effectiveness in preventing atrial fibrillation after coronary artery bypass graft surgery Zebis LR, Christensen TD, Kristiansen IS, Hjortdal VE Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the clinical and economic impact of using postoperative amiodarone for the prevention of atrial fibrillation in patients undergoing a coronary artery bypass graft for stable angina. The authors concluded that the prophylactic use of amiodarone reduced the risk of atrial fibrillation

NHS Economic Evaluation Database.2008

28. Quality of life with defibrillator therapy or amiodarone in heart failure.

Quality of life with defibrillator therapy or amiodarone in heart failure. 18768943 2008 09 04 2008 09 11 2016 11 22 1533-4406 359 10 2008 Sep 04 The New England journal of medicine N. Engl. J. Med. Quality of life with defibrillator therapy or amiodarone in heart failure. 999-1008 10.1056/NEJMoa0706719 Implantable cardioverter-defibrillator (ICD) therapy significantly prolongs life in patients at increased risk for sudden death from depressed left ventricular function. However, whether (...) this increased longevity is accompanied by deterioration in the quality of life is unclear. In a randomized trial, we compared ICD therapy or amiodarone with state-of-the-art medical therapy alone in 2521 patients who had stable heart failure with depressed left ventricular function. We prospectively measured quality of life at baseline and at months 3, 12, and 30; data collection was 93 to 98% complete. The Duke Activity Status Index (which measures cardiac physical functioning) and the Medical Outcomes

NEJM2008 Full Text: Link to full Text with Trip Pro

29. Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial.

Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. 18854540 2008 10 15 2008 10 20 2016 10 17 1538-3598 300 15 2008 Oct 15 JAMA JAMA Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. 1784-92 10.1001/jama.300.15.1784 Amiodarone effectively suppresses atrial fibrillation but causes many adverse events. To compare major events in patients randomized (...) to receive episodic amiodarone treatment with those who received continuous amiodarone treatment while still aiming to prevent atrial fibrillation. A randomized trial of 209 ambulatory patients with recurrent symptomatic persistent atrial fibrillation, conducted from December 2002 through March 2007 at 7 Dutch medical centers. Patients were randomly assigned to receive either episodic or continuous amiodarone treatment after electrical cardioversion following amiodarone loading. Episodic amiodarone

JAMA2008

30. Prescribing amiodarone: an evidence-based review of clinical indications.

Prescribing amiodarone: an evidence-based review of clinical indications. CONTEXT: Although amiodarone is approved by the US Food and Drug Administration only for refractory ventricular arrhythmias, it is one of the most frequently prescribed antiarrhythmic medications in the United States. OBJECTIVE: To evaluate and synthesize evidence regarding optimal use of amiodarone for various arrhythmias. EVIDENCE ACQUISITION: Systematic search of MEDLINE to identify peer-reviewed clinical trials (...) , randomized controlled trials, meta-analyses, and other studies with clinical pertinence. The search was limited to human-participant, English-language reports published between 1970 and 2007. Amiodarone was searched using the terms adverse effects, atrial fibrillation, atrial flutter, congestive heart failure, electrical storm, hypertrophic cardiomyopathy, implantable cardioverter-defibrillator, surgery, ventricular arrhythmia, ventricular fibrillation, and Wolff-Parkinson-White. Bibliographies

JAMA2007

31. Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation

Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation Buckley M S, Nolan P E, Slack M K, Tisdale J E, Hilleman D E, Copeland J G CRD summary This review concluded that total (...) amiodarone doses of 3,000 mg or higher may be more effective than lower doses in reducing the rate of post-operative atrial fibrillation after cardiac surgery. Pre-operative initiation of amiodarone appears to be unnecessary. Given the potential weaknesses in the review methods and analyses, it is difficult to assess the robustness of the authors' conclusions. Authors' objectives To assess optimal dosing regimens of prophylactic amiodarone for reducing the incidence of atrial fibrillation (AF) after

DARE.2007

32. Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone

Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone Caro J J, Ward A, Deniz H B, O'Brien J A, Ehreth J L Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study evaluated the economic value of an implantable cardioverter defibrillator (ICD) in comparison with amiodarone therapy for the primary prevention of sudden cardiac death in patients with heart failure, using a cost-benefit analysis. The authors

NHS Economic Evaluation Database.2007

33. Drugs - Amiodarone

Drugs - Amiodarone Amiodarone AMO Drugs October 2006 Page 1 of 1 Drugs PRESENTATION Pre-filled syringe containing 300 milligrams amiodarone in 10ml. ACTIONS Class 3 antiarrhythmic, lengthens cardiac action potential & therefore effective refractory period and QT interval on ECG. Blocks potassium channels in cardiac muscle. Signi?cant sodium channel blocking activity. INDICATIONS Ventricular ?brillation (VF) or pulseless ventricular tachycardia (VT) refractory to de?brillating shocks. CONTRA

Joint Royal Colleges Ambulance Liaison Committee2007

34. An implantable cardioverter defibrillator but not amiodarone reduced risk of death in congestive heart failure

An implantable cardioverter defibrillator but not amiodarone reduced risk of death in congestive heart failure An implantable cardioverter defibrillator but not amiodarone reduced risk of death in congestive heart failure | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here An implantable cardioverter defibrillator but not amiodarone reduced risk of death in congestive heart failure Article Text Therapeutics An implantable cardioverter defibrillator but not amiodarone reduced risk of death in congestive heart failure Free Andrew Corsello , MD Statistics

Evidence-Based Medicine (Requires free registration)2006

35. Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis

Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis Bagshaw S M, Galbraith P D, Mitchell L B, Sauve R, Exner D V, Ghali W A CRD summary This review evaluated the effects of amiodarone in post-operative atrial fibrillation. It concluded (...) that amiodarone prophylaxis is associated with a significant reduction in atrial fibrillation after cardiac surgery, as well as a reduction in peri-operative ventricular tachyarrhythmias and strokes and a short but significant reduction in hospital stay. The authors' conclusions reflect the evidence presented and are likely to be reliable. Authors' objectives To evaluate the effect of amiodarone in post-operative atrial fibrillation (AF). Searching MEDLINE, EMBASE and the Cochrane Controlled Trials Register

DARE.2006

36. Amiodarone

Amiodarone Amiodarone AMO Drugs October 2006 Page 1 of 1 Drugs PRESENTATION Pre-filled syringe containing 300 milligrams amiodarone in 10ml. ACTIONS Class 3 antiarrhythmic, lengthens cardiac action potential & therefore effective refractory period and QT interval on ECG. Blocks potassium channels in cardiac muscle. Signi?cant sodium channel blocking activity. INDICATIONS Ventricular ?brillation (VF) or pulseless ventricular tachycardia (VT) refractory to de?brillating shocks. CONTRA-INDICATIONS

Joint Royal Colleges Ambulance Liaison Committee2006

37. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.

Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. 16403928 2006 01 11 2006 01 13 2016 10 17 1538-3598 295 2 2006 Jan 11 JAMA JAMA Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. 165-71 Implantable cardioverter defibrillator (ICD) therapy (...) is effective but is associated with high-voltage shocks that are painful. To determine whether amiodarone plus beta-blocker or sotalol are better than beta-blocker alone for prevention of ICD shocks. A randomized controlled trial with blinded adjudication of events of 412 patients from 39 outpatient ICD clinical centers located in Canada, Germany, United States, England, Sweden, and Austria, conducted from January 13, 2001, to September 28, 2004. Patients were eligible if they had received an ICD within 21

JAMA2006

38. Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis

Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis Aasbo J D, Lawrence A T, Krishnan K, Kim M H, Trohman R G CRD summary The authors assessed the use of prophylactic amiodarone given around (...) the time of cardiac surgery. They found that the incidence of atrial fibrillation or flutter, ventricular tachycardia or fibrillation, and stroke were reduced by amiodarone. Length of hospital stay was also reduced, but there was no difference in death rates. The review was well conducted and the results appear reliable. Authors' objectives To assess whether prophylactic amiodarone decreases the incidence of major cardiovascular morbidity, length of hospital stay and mortality after cardiac surgery

DARE.2005

39. Prophylactic Oral Amiodarone for the Prevention of Arrhythmias that Begin Early After Revascularization, Valve Replacement, or Repair: PAPABEAR: a randomized controlled trial.

Prophylactic Oral Amiodarone for the Prevention of Arrhythmias that Begin Early After Revascularization, Valve Replacement, or Repair: PAPABEAR: a randomized controlled trial. 16380589 2005 12 28 2005 12 30 2016 10 17 1538-3598 294 24 2005 Dec 28 JAMA JAMA Prophylactic Oral Amiodarone for the Prevention of Arrhythmias that Begin Early After Revascularization, Valve Replacement, or Repair: PAPABEAR: a randomized controlled trial. 3093-100 Atrial tachyarrhythmias after cardiac surgery (...) are associated with adverse outcomes and increased costs. Previous trials of amiodarone prophylaxis, while promising, were relatively small and yielded conflicting results. To determine whether a brief perioperative course of oral amiodarone is an effective and safe prophylaxis for atrial tachyarrhythmias after cardiac surgery overall and in important subgroups. Double-blind randomized controlled trial of 601 patients listed for nonemergent coronary artery bypass graft (CABG) surgery and/or valve replacement

JAMA2005

40. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. 15659722 2005 01 20 2005 01 27 2013 11 21 1533-4406 352 3 2005 Jan 20 The New England journal of medicine N. Engl. J. Med. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. 225-37 Sudden death from cardiac causes remains a leading cause of death among patients with congestive heart failure (CHF). Treatment with amiodarone or an implantable cardioverter-defibrillator (ICD (...) ) has been proposed to improve the prognosis in such patients. We randomly assigned 2521 patients with New York Heart Association (NYHA) class II or III CHF and a left ventricular ejection fraction (LVEF) of 35 percent or less to conventional therapy for CHF plus placebo (847 patients), conventional therapy plus amiodarone (845 patients), or conventional therapy plus a conservatively programmed, shock-only, single-lead ICD (829 patients). Placebo and amiodarone were administered in a double-blind

NEJM2005